Results 181 to 190 of about 2,386,085 (253)

A sustainable business ecosystem: a case study demonstrating biochar's potential

Biofuels, Bioproducts and Biorefining, EarlyView.
Abstract The need for renewable, climate‐friendly resources has become urgent as legislators worldwide have sought to find ways to cut emissions while ensuring resource security for consumers. The use of biochar could help to achieve these goals. This study examines the current state of commercial biochar production and the maturity of the related ...
Juuso Kivijakola, Eemeli Erkheikki, Viljo Lukka, Pekka Tervonen, Harri Haapasalo   +4 more
wiley   +1 more source

Vision 2040 in Japan: renewing UHC through community-based health care and health security. [PDF]

Lancet Reg Health West Pac
The Lancet Regional Health-Western Pacific.
europepmc   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Financial Fraud Victimization Among Young Adults in Taiwan: Roles of Executive Functioning, Personality Traits, and the Self-Reported Attention-Deficit/Hyperactivity Disorder Diagnosis. [PDF]

Brain Behav
Yeh YC, Lin PC, Lin CY, Chang YP, Wang PW, Yen CF.   +5 more
europepmc   +1 more source

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

Immigrants' Gendered Remittance-Sending Patterns and Purposes: The Role of Marital Status. [PDF]

Can Rev Sociol
Dicks H, Kaida L, Swiss L.
europepmc   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković   +4 more
wiley   +1 more source

Ethics of child suffering imagery in the context of exploding digital technologies. [PDF]

BMJ Paediatr Open
Khoo EJ, Goldhagen J, Wise PH.
europepmc   +1 more source

The market for human smuggling: Structure, mechanisms, and paradoxes. [PDF]

Proc Natl Acad Sci U S A
Campana P.
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source